KURA

Kura Oncology, Inc. (KURA) Economic Moat Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Profitability Returns

Gross margin remains very high at 94.7%, but operating profitability is still deeply negative with EBIT margin at -3.8% and ROIC at -67.0%.

Return on equity remains sharply negative at -207.2%, indicating the business is still not generating shareholder returns.

Balance Sheet Financial Flexibility

Liquidity remains strong with a current ratio of 4.73 and quick ratio of 4.71, supported by cash per share of 5.84.

Leverage remains manageable with debt-to-equity at 0.50 and debt-to-assets at 0.04, though the company is still unprofitable.

Efficiency Capital Intensity

Asset turnover remains low at 0.13, suggesting limited revenue generation from the asset base.

Working capital remains positive at $441.2M, but operating cash flow and free cash flow are still negative.

Valuation Moat Signals

The company still trades at a rich valuation with EV/Sales of 11.9x and Price/Sales of 12.5x despite negative earnings and cash flow.

High R&D intensity at 336.0% of revenue suggests ongoing investment in pipeline development, but there is still no clear evidence of durable economic moat from current financials.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Kura Oncology, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →